EUVIMEDEUVIMED entdecken
Crossref

Oligonucleotide‐Linked Lipid Nanoparticles as a Versatile mRNA Nanovaccine Platform

San Hae Im, Youseung Chung, Nevena Duskunovic, Heewon Choi, Su-Hyung Park, Hyun Jung Chung iD

Advanced Healthcare Materials · 2024-12 · 13 (31)

DOI: 10.1002/adhm.202401868 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 03.10.2024. Verfasst von San Hae Im und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea. Hauptthemen laut MEDLINE: Nanoparticles, SARS-CoV-2, RNA, Messenger, COVID-19 Vaccines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Research Foundation of Korea, Yuhan Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An effective delivery platform is crucial for the development of mRNA vaccines and therapeutics. Here, a versatile platform utilizing cholesterol‐modified oligonucleotides (L‐oligo) that bind to the mRNA within lipid nanoparticles (LNP), and enables the effective delivery of the mRNA into target cells is introduced. mRNA incorporated into LNPs via linkage with L‐oligo, termed oligonucleotide‐linked LNP (lnLNP), is superior in cellular uptake and transfection efficiency in target cells in vitro and in vivo, compared to the conventional LNP formulations. It is further applied lnLNP as an mRNA vaccine platform for SARS‐CoV‐2, demonstrating robust induction of neutralizing activity as well as polyfunctional SARS‐CoV‐2‐specific T‐cell response in vivo. The current strategy can be versatilely applied to different LNP platforms, for vaccine and therapeutic applications against various diseases, such as infections and cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesSARS-CoV-2RNA, MessengerCOVID-19 VaccinesOligonucleotidesCOVID-19AnimalsHumansMiceLipidsMice, Inbred BALB CmRNA VaccinesFemaleNanovaccinesLiposomes

Stichwörter der Autor:innen

linker oligonucleotidelipid nanoparticlemRNA deliveryvaccine

Substanzen

RNA, MessengerCOVID-19 VaccinesOligonucleotidesLipid NanoparticlesLipidsmRNA VaccinesNanovaccinesLiposomes

Autor:innen und Institutionen

  • Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea.
  • Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea.
  • The Center for Epidemic Preparedness, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea.

ORCID-Profile: Hyun Jung Chung

Förderung

  • National Research Foundation of Korea
  • Yuhan Corporation

Zitieren

APA

Im, S. H., Chung, Y., Duskunovic, N., Choi, H., Park, S. H., & Chung, H. J. (2024). Oligonucleotide‐Linked Lipid Nanoparticles as a Versatile mRNA Nanovaccine Platform. Advanced Healthcare Materials, 13(31). https://doi.org/10.1002/adhm.202401868

Vancouver

Im SH, Chung Y, Duskunovic N, Choi H, Park SH, Chung HJ. Oligonucleotide‐Linked Lipid Nanoparticles as a Versatile mRNA Nanovaccine Platform. Advanced Healthcare Materials. 2024;13(31). doi:10.1002/adhm.202401868

BibTeX
@article{Im2024,
  author = {Im, San Hae and Chung, Youseung and Duskunovic, Nevena and Choi, Heewon and Park, Su-Hyung and Chung, Hyun Jung},
  title = {Oligonucleotide‐Linked Lipid Nanoparticles as a Versatile mRNA Nanovaccine Platform},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  volume = {13},
  number = {31},
  doi = {10.1002/adhm.202401868}
}
Kostenlos starten →